News

• 2022.10.12
  Cellusion and Minaris Regenerative Medicine, a Member of Showa Denko Materials, Enter into Business...
• 2022.10.11
  Dr. Hatou presented Cellusion business progress in the 2022 Cell & Gene Meeting on the Mesa
• 2022.09.12
  Cellusion and Celregen, a member of Fosun Pharma, Enter into License Agreement of CLS001
• 2022.08.01
  Cellusion moves the HQs in Nihonbashi-Kobuna Area
• 2022.07.07
  A joint research paper between Cellusion and Keio University published in STEM CELLS Translational ...
• 2022.06.29
  The CLS001 FIH study infomaiton was disclosed in jRCT.
• 2022.06.14
  Dr. Hatou presented Cellusion business progress in the BIO International Convention.
• 2022.04.20
  Dr. Hatou presented Cellusion business progress in the 2022 Cell & Gene Meeting on the Med.
• 2022.03.23
  Public Announcement of Financial Results of the 7th Fiscal Year and Capital Reduction
• 2022.03.23
  Cellusion and Toyo Seikan Group Holdings enter Capital and Business Alliance of CLS001 for Corneal ...
• 2022.03.01
  Cellusion established the Board of Corporate Auditors
• 2022.03.01
  Announcement of Changes to Officer Personnel
• 2022.01.18
  Cellusion's Series B fundraising was introduced in BioWorld
• 2022.01.07
  Cellusion obtained JHVS Venture Award 2021
• 2022.01.07
  Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothe...
• 2022.01.07
  Cellusion and Toho Holdings enter Capital and Business Alliance of CLS001 for Corneal Endothelial C...
• 2022.01.07
  Cellusion welcomes Dr. Naonori Kurokawa and Dr. Hiroaki Kobayashi to the Management Team
• 2021.11.16
  Cellusion obtained 1st prize of JHVS2021 Global Pitch
• 2021.10.30
  Cellusion participated the mini seminar in ISSCR & JSRM 2021 Tokyo International Symposium "Stem Ce...
• 2021.10.12
  Dr. Hatou presented Cellusion business progress in the 2021 Cell & Gene Meeting on the Mesa.
• 2021.10.05
  Cellusion obtained 1st prize of Boehringer Ingelheim Innovation Prize 2021
• 2021.08.31
  Cellusion welcomes Stella and Toru as new board members
• 2021.08.23
  CLS001 Non-clinical Efficacy Study Result was published in Stem Cell Research.
• 2021.07.16
  CLS001 Clinical Study Plan Officially Approved by MHLW‘s Health Science Council
• 2021.07.02
  The Clinical Study Plan on Corneal Endothelial Cell Substitute from iPS Cells Transplant Plan for B...
• 2021.06.21
  Dr. Hatou presents recent research progress in 2021 ISSCR VIRTUAL conference.
• 2021.06.08
  Keio Univ.'s Corneal Endothelial Cell Substitute from iPS Cells Transplant Plan on Bullous Keratopa...
• 2021.04.06
  Cellusion introduced in The Nikkan Kogyo Shimbun.
• 2021.03.11
  Dr. Hatou ＆ Dr. Sayano presented recent research progress in the 20th Congress of the Japanese Soci...
• 2021.02.19
  Dr. Hatou introduced our business plan in RINK FESTIVAL 2021.
• 2021.02.12
  Dr. Hatou presented recent research progress in Japan Cornea Conference 2021.
• 2020.12.09
  Dr. Hatou presented Cellusion business progress in Genesis Digital 2020
• 2020.06.29
  Dr. Hatou presented recent research progress in 2020 ISSCR virtual conference.
• 2020.05.31
  Cellusion raises additional funding and welcomes a new board member
• 2020.01.16
  Cellusion moves HQ and opens a new laboratory in Nihombashi
• 2020.01.14
  Cellusion selected as J-TECH STARTUP 2019
• 2020.01.14
  Cellusion raises 360M JPY in series A funding
• 2019.10.10
  Cellusion selected as JHVS2019 Venture Award.
• 2019.10.09
  Cellusion Introduction Video Released
• 2019.09.12
  Cellusion has been selected Tokyo metropolitan government R&D facility support grant 2019.
• 2019.08.01
  Cellusion introduced in Co-founders site.
• 2019.07.30
  Cellusion introduced in KII investment stories.
• 2019.07.06
  Cellusion introduced in Nikkei article.
• 2019.06.29
  Dr. Hatou presented recent research progress in 2019 ISSCR annual conference.
• 2019.06.12
  Cellusion has been selected to NEDO STS program 2019